M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Final Results of a Phase II Study Evaluating Lenalidomide in Combination with Low Dose Dexamethasone As First Line Therapy for Primary Plasma Cell Leukemia
Pellegrino Musto,Fiorella D'Auria,Maria Teresa Petrucci,Anna Levi,Nicola Cascavilla,Antonietta Falcone,Francesco Di Raimondo,Maide Cavalli,Tommaso Caravita,Fortunato Morabito,Massimo Offidani,Nunzio Filardi,Francesco Nobile,Giulia Benevolo,Giuseppe Pietrantuono,Maria Carmen Martorelli,Oreste Villani,Roberto Guariglia,Giovanna Mansueto,Giovanni D'Arena,Rosa Lerose,Antonia Zonno,Emanuela Zifarone,Valentina Santopietro,Katia Todoerti,Sara Bringhen,Paola Omedè,Antonino Neri,Mario Boccadoro,Antonio Palumbo +29 more
TL;DR: A multicenter, phase II trial aiming to evaluate safety and antitumor activity of lenalidomide in combination with dexamethasone (LD) in previously untreated primary plasma cell leukemia, with results reported on May, 31, 2011.
Journal ArticleDOI
Bortezomib-Based Induction Treatments Improve Outcomes of Newly Diagnosed Multiple Myeloma Patients with High-Risk Cytogenetic Abnormalities
Michele Cavo,Sara Bringhen,Carolina Terragna,Paola Omedè,Giulia Marzocchi,Marina Ruggeri,Sandra Durante,Maria Teresa Petrucci,Tommasina Guglielmelli,Giulia Benevolo,Vittorio Montefusco,Franco Narni,Antonietta Falcone,Catello Califano,Anna Baraldi,Silvana Pasini,Piero Galieni,Fortunato Morabito,Mariella Grasso,Daniela Gottardi,Vincenzo Rizzo,Mario Boccadoro,Nicoletta Testoni,Antonio Palumbo +23 more
TL;DR: The rates of absence or presence of del (13q), t(4;14) and/or del(17p) were comparable among patients receiving VTD or V MP or VMPT treatments, and the prognostic relevance of high-risk cytogenetic abnormalities was evaluated.
Journal ArticleDOI
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives.
Marta Coscia,Candida Vitale,Marco Cerrano,Enrico Maffini,Luisa Giaccone,Mario Boccadoro,Benedetto Bruno +6 more
TL;DR: A comprehensive overview of the current role of CAR T cell therapies in hematological malignancies and solid tumors, their associated toxicities and potential future developments in the armamentarium for cancer treatment is provided.
Journal ArticleDOI
Immunomodulatory and clinical effects of daratumumab in T-cell acute lymphoblastic leukaemia.
Marco Cerrano,Barbara Castella,Giuseppe Lia,Matteo Olivi,Danilo Faraci,Sara Butera,Federica Martella,M Scaldaferri,Francesco Cattel,Mario Boccadoro,Massimo Massaia,Dario Ferrero,Benedetto Bruno,Luisa Giaccone +13 more
TL;DR: The prompt use of agents which target the underlying pathophysiology of RA remains the best option for the prevention of potential damage in patients, who usually present with comorbidities due to SCD.
Journal ArticleDOI
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment.
Chiara Lobetti-Bodoni,Dario Ferrero,Elisa Genuardi,Roberto Passera,Elisa Bernocco,Daniela Sia,Giovanni Grignani,Elena Crisà,Luigia Monitillo,Alberto Rocci,Daniela Drandi,Valentina Giai,Manuela Zanni,Michela Boi,Gianluca Isaia,Daniela Barbero,Monia Lunghi,Elisabetta Abruzzese,F. Radaelli,Massimo Pini,Patrizia Pregno,Carmelo Carlo-Stella,Gianluca Gaidano,Mario Boccadoro,Marco Ladetto +24 more
TL;DR: CML patients suffer from significant and often ongoing telomere stress resulting in premature and selective aging of the myeloid compartment which might have long-term consequences on function and integrity of Ph-negative hematopoiesis.